Alli is the first and only FDA-approved OTC product for weight loss. It is available in stores June 15. Dr. James Anderson, UK HealthCare weight loss researcher, studied the effects of the drug on mildly to moderately overweight individuals and found it does aid weight loss.
Heart attack patients received life-saving care up to an hour sooner after an Indiana hospital implemented a novel protocol to rapidly activate the cardiac catheterization lab, researchers reported in Circulation: Journal of the American Heart Association.
Countless exercise programs claim to trim the thighs, abs and buttocks, but how many offer to reshape a flabby heart? According to new research, aerobic exercise does just that for patients with stable heart failure, literally turning an enlarged heart into a trimmer, more efficient organ for pumping blood throughout the body.
Look at the clock. In the next three minutes, 10 people in America will suffer a coronary event or stroke, and only six of them will survive. According to a recent report by the American Heart Association (AHA), coronary heart disease (CHD) affects more than 15 million Americans; over five million more are affected by stroke.
Men whose blood tests positive for the auto-antibody rheumatoid factor have a three times higher risk of heart disease, according to a study published online ahead of print in Heart.
By uncovering how one breast cancer drug protects the heart and another does not, Duke University Medical Center researchers believe they may have opened up a new way to screen drugs for possible heart-related side effects and to develop new drugs.
The American Heart Association/American Stroke Association has awarded two Get With the Guidelines Annual Performance Achievement Awards to Strong Memorial Hospital of the University of Rochester Medical Center for meeting its high standards for coronary artery disease and stroke care.
Blocking a single protein with an experimental drug prevented and treated both type 2 diabetes and atherosclerosis in laboratory mice that had been fed unhealthy diets and were genetically predisposed to these common killers, according to an article published online at Nature on June 6, 2007.
A study of more than 33,000 type 2 diabetes patients in a real-world setting was published today. This study shows that the incidence of hospitaliations for heart attack, and/or for a surgery known as coronary revascularization for patients on Avandia is the same as for other diabetes treatments.
On June 5, 2007, the New England Journal of Medicine published results of an interim analysis of the cardiovascular safety trial of rosiglitazone (brand name, Avandia).